Foreign-Trade Zone (FTZ) 29, Notification of Proposed Production Activity; Catalent Pharma Solutions, LLC (Catalent); (Nonsteroidal Antiandrogen Tablets); Winchester, Kentucky, 52022 [2024-13534]

Download as PDF 52022 Federal Register / Vol. 89, No. 120 / Friday, June 21, 2024 / Notices households and is designed to supplement the federal statistical system’s traditional benchmark data products with a new data source that provides relevant and timely information based on a high-quality sample frame, data integration, and cooperative expertise. Affected Public: Households. Frequency: Households will be selected once to participate in a 20minute survey. Respondent’s Obligation: Voluntary. Legal Authority: Title 13, United States Code, Sections 8(b), 182 and 193. This information collection request may be viewed at www.reginfo.gov. Follow the instructions to view the Department of Commerce collections currently under review by OMB. Written comments and recommendations for the proposed information collection should be submitted within 30 days of the publication of this notice on the following website www.reginfo.gov/ public/do/PRAMain. Find this particular information collection by selecting ‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the search function and entering either the title of the collection or the OMB Control Number 0607–1029. Sheleen Dumas, Department PRA Clearance Officer, Office of the Under Secretary for Economic Affairs, Commerce Department. [FR Doc. 2024–13668 Filed 6–20–24; 8:45 am] BILLING CODE 3510–07–P DEPARTMENT OF COMMERCE Foreign-Trade Zones Board [B–34–2024] ddrumheller on DSK120RN23PROD with NOTICES1 Foreign-Trade Zone (FTZ) 29, Notification of Proposed Production Activity; Catalent Pharma Solutions, LLC (Catalent); (Nonsteroidal Antiandrogen Tablets); Winchester, Kentucky Catalent submitted a notification of proposed production activity to the FTZ Board (the Board) for its facility in Winchester, Kentucky within FTZ 29. The notification conforming to the requirements of the Board’s regulations (15 CFR 400.22) was received on June 11, 2024. Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status material(s)/ component(s) and specific finished product(s) described in the submitted notification (summarized below) and subsequently authorized by the Board. VerDate Sep<11>2014 17:46 Jun 20, 2024 Jkt 262001 The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board’s website—accessible via www.trade.gov/ ftz. The proposed finished products include: nonsteroidal antiandrogen tablets (duty-free). The proposed foreign-status materials/components include: apalutamide (active pharmaceutical ingredient) (duty rate of 6.5%). Public comment is invited from interested parties. Submissions shall be addressed to the Board’s Executive Secretary and sent to: ftz@trade.gov. The closing period for their receipt is July 31, 2024. A copy of the notification will be available for public inspection in the ‘‘Online FTZ Information System’’ section of the Board’s website. For further information, contact Kolade Osho at Kolade.Osho@trade.gov. Dated: June 14, 2024. Elizabeth Whiteman, Executive Secretary. [FR Doc. 2024–13534 Filed 6–20–24; 8:45 am] BILLING CODE 3510–DS–P DEPARTMENT OF COMMERCE Bureau of Industry and Security In the Matter of: USGoBuy, LLC, 6804 NE 79th Ct., Building A, Portland, OR 97218, Respondent; Order Activating Suspended Portion of Civil Penalty and Activating Suspended Denial of Export Privileges Against USGoBuy, LLC On June 17, 2021, then-Acting Assistant Secretary of Commerce for Export Enforcement, Kevin J. Kurland signed an order (the ‘‘June 17, 2021 Order’’) approving the terms of a settlement agreement (the ‘‘Settlement Agreement’’) between the Bureau of Industry and Security, U.S. Department of Commerce (‘‘BIS’’), and USGoBuy, LLC (‘‘USGoBuy’’ or ‘‘the Company’’). USGoBuy is a package forwarding company based in Portland, Oregon that offers a service that allows non-U.S.based customers to purchase items online from U.S. retailers and have those items shipped to the Company’s warehouse in Oregon. USGoBuy then consolidates various items ordered by its customers and re-packages the items for export from the United States. USGoBuy also offers a ‘‘BuyForMe’’ service in which it purchases U.S.origin items on behalf of its customers, and then exports the items to a foreign addressee and address provided by the customer. PO 00000 Frm 00013 Fmt 4703 Sfmt 4703 The Settlement Agreement and the June 17, 2021 Order relate to an enforcement action brought by BIS against USGoBuy for exporting riflescopes, items classified under Export Control Classification Number (‘‘ECCN’’) 0A987.a, controlled for Crime Control reasons, to China and the United Arab Emirates, without seeking or obtaining the licenses required for these exports, in violation of the Export Administration Regulations (the ‘‘Regulations’’).1 The Settlement Agreement and June 17, 2021 Order imposed on USGoBuy a civil penalty of $20,000. USGoBuy was required to pay $5,000 of this amount to the Department of Commerce by July 17, 2021. Payment of the remaining $15,000 was suspended for a probationary period of three years from the date of the June 17, 2021 Order, after which it would be waived, provided that during this three-year probationary period, USGoBuy paid the $5,000 nonsuspended portion of the civil penalty, committed no other violation of the Regulations, and completed an independent, external audit (the ‘‘Export Compliance Audit’’ or ‘‘Audit’’). The June 17, 2021 Order required that the Export Compliance Audit cover the 12-month period after the June 17, 2021 Order and be in substantial compliance with the Export Compliance Program sample audit module published by BIS. To the extent USGoBuy identified any violations of the Regulations through the Audit, the June 17, 2021 Order required USGoBuy to promptly provide supporting documentation related to the violations and a detailed plan of corrective actions to be taken. In addition, the June 17, 2021 Order also imposed a three-year denial of USGoBuy’s export privileges under the Regulations. This denial order was suspended pursuant to section 766.18(c) of the Regulations, subject to the same probationary conditions described above. According to the June 17, 2021 Order, if USGoBuy failed to make full and timely payment of the nonsuspended penalty, did not complete the audit and submit the results as required by the Settlement Agreement, or if USGoBuy committed additional violations of the Regulations during the three-year probationary period, BIS could modify or revoke the suspended 1 The Regulations are currently codified in the Code of Federal Regulations at 15 CFR parts 730– 774 (2024). The violations at issue in the Settlement Agreement occurred in 2015. The Regulations governing those violations are found in the 2015 version of the Code of Federations (15 CFR parts 730–774). The 2024 Regulations set forth the procedures that apply to this matter. E:\FR\FM\21JNN1.SGM 21JNN1

Agencies

[Federal Register Volume 89, Number 120 (Friday, June 21, 2024)]
[Notices]
[Page 52022]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-13534]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-34-2024]


Foreign-Trade Zone (FTZ) 29, Notification of Proposed Production 
Activity; Catalent Pharma Solutions, LLC (Catalent); (Nonsteroidal 
Antiandrogen Tablets); Winchester, Kentucky

    Catalent submitted a notification of proposed production activity 
to the FTZ Board (the Board) for its facility in Winchester, Kentucky 
within FTZ 29. The notification conforming to the requirements of the 
Board's regulations (15 CFR 400.22) was received on June 11, 2024.
    Pursuant to 15 CFR 400.14(b), FTZ production activity would be 
limited to the specific foreign-status material(s)/component(s) and 
specific finished product(s) described in the submitted notification 
(summarized below) and subsequently authorized by the Board. The 
benefits that may stem from conducting production activity under FTZ 
procedures are explained in the background section of the Board's 
website--accessible via www.trade.gov/ftz.
    The proposed finished products include: nonsteroidal antiandrogen 
tablets (duty-free).
    The proposed foreign-status materials/components include: 
apalutamide (active pharmaceutical ingredient) (duty rate of 6.5%).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
[email protected]. The closing period for their receipt is July 31, 2024.
    A copy of the notification will be available for public inspection 
in the ``Online FTZ Information System'' section of the Board's 
website.
    For further information, contact Kolade Osho at 
[email protected].

    Dated: June 14, 2024.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2024-13534 Filed 6-20-24; 8:45 am]
BILLING CODE 3510-DS-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.